drugset / Trial / NCT03645486
Lentiviral Gene Therapy for CGD
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I/II clinical trial of gene therapy for treating Chronic Granulomatous Disease using a high-safety, high-efficiency, self-inactivating lentiviral vector TYF to functionally correct the defective gene. The objectives are to evaluate the safety and efficacy of the TYF-CGD gene transfer clinical protocol.
Timeline
- Start
- 2025-07-01
- Primary completion
- 2028-06-30
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TYF-CGD-modified autologous stem cells | Cell therapy | 1e+06 cells/kg | — |
| Subject | TYF-CGD-modified autologous stem cells | Cell therapy | 1e+07 cells/kg | — |